Evidence map›Paper›PMID 38668707›Full record

ArticleJournal of medicinal chemistry2024

Design, Synthesis, and Investigation of the Pharmacokinetics and Anticancer Activities of Indenoisoquinoline Derivatives That Stabilize the G-Quadruplex in the

Yichen Han, Adam Buric, Venkat Chintareddy, Mercedes DeMoss, Luying Chen, Jonathan Dickerhoff, Robyn De Dios, Pooran Chand, Randall Riggs, Danzhou Yang and 1 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Targeting MYC-Driven Cancers: From Oncogenic Addiction to Therapeutic Vulnerability.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Design, Synthesis and Bioactive Evaluation of Topo I/Molecules (Basel, Switzerland) · 2025
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yichen HanBorch Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States.ORCID 0000-0002-1034-2958
Adam BuricBorch Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States.
Venkat ChintareddyTherachem Research Medilab LLC, 100 Jade Park, Chelsea, Alabama 35043, United States.
Mercedes DeMossBorch Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States.
Luying ChenBorch Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States.
Jonathan DickerhoffBorch Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States.ORCID 0000-0002-3197-9472
Robyn De DiosDepartment of Chemistry, Purdue University, West Lafayette, Indiana 47907, United States.
Pooran ChandTherachem Research Medilab LLC, 100 Jade Park, Chelsea, Alabama 35043, United States.
Randall RiggsGibson Oncology, 7772 Fisher Island Drive, Miami, Florida 33109, United States.
Danzhou YangBorch Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States.ORCID 0000-0001-7489-7111
Mark CushmanBorch Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States.ORCID 0000-0002-0152-5891

Funding

Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI Andrea L Kasinski · 1985 to 2026
$43.4M
Targeting MYC promoter G-quadruplex for MYC inhibition by IndenoisoquinolinesR01CA177585 · NCI · UNIVERSITY OF ARIZONA · PI SINTIM, HERMAN O, YANG, DANZHOU · 2014 to 2025
$4.0M
Nucleolin recognition of MYC promoter G-quadruplex and its role in MYC regulation by MycG4-ligandsU01CA240346 · NCI · PURDUE UNIVERSITY · PI YANG, DANZHOU · 2020 to 2024
$2.1M
Purdue University Molecular Biophysics Training ProgramT32GM132024 · NIGMS · PURDUE UNIVERSITY · PI Angeline Marie Lyon, John Tesmer · 2019 to 2026
$2.0M
Purdue Drug Discovery Training ProgramT32GM125620 · NIGMS · PURDUE UNIVERSITY · PI DYKHUIZEN, EMILY CARLA, WEI, ALEXANDER · 2019 to 2023
$891k
NCI NIH HHS P30 CA023168NCI NIH HHS R01 CA177585NCI NIH HHS U01 CA240346NIGMS NIH HHS T32 GM125620NIGMS NIH HHS T32 GM132024
6 · The paper itself

Abstract

G-quadruplexes are noncanonical four-stranded DNA secondary structures.

Indexed as

Antineoplastic AgentsDrug DesignG-QuadruplexesIsoquinolinesPromoter Regions, GeneticProto-Oncogene Proteins c-mycTopoisomerase I InhibitorsAnimalsCell Line, TumorDNA Topoisomerases, Type IHumansMiceStructure-Activity RelationshipXenograft Model Antitumor AssaysAntineoplastic AgentsDNA Topoisomerases, Type IIsoquinolinesProto-Oncogene Proteins c-mycTopoisomerase I Inhibitors

Identifiers

PMID38668707
PMCPMC11134171

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.